Company Overview and News
DOUBLEDRAGON Properties Corp. on Wednesday said it is “generally unaffected” by rising interest rates and weakening peso, as the company’s borrowings are all peso-denominated and have fixed rates.
THE PHILIPPINE STOCK EXCHANGE index (PSEi) exited bear territory on Friday amid what one analyst described as “a dizzying rally”, but its strong recovery was not enough to prevent its third straight week-on-week drop.
FPHPC MPCIY BDOUY AYAAY UVRBY AEV FPHP DD SECB MRAIF BDOUF BDO ABTZY MPI MPCFF SYBJF URC MRC ALI FPH UVRBF AYAAF
THE MANILA BAY Area is expected to grow its total office stock by 130% by 2021, as tenants look for alternative locations given the lack of office spaces in Metro Manila’s two leading business districts.
CAPITAL raised at the stock market reached a record P150 billion in the first half, as companies braved the local market amid prevailing volatility.
IRC PSKXF CHIB SUAFF RBLAY BSC DD CKGOY RLC PHSXY PSE FNI BCDTY
DoubleDragon Properties Corp. on Tuesday said it has started construction for its second industrial leasing hub in Iloilo.
2018-06-07 business.inquirer.net - 1
Property developer DoubleDragon Properties Corp. is set to unveil today Islas Pinas, a new Filipino culinary and heritage village developed in collaboration with celebrity chef Margarita Fores, as the centerpiece of its maiden office development DoubleDragon Plaza.
PSKXF PHSXY PSE DD
DOUBLEDRAGON PROPERTIES Corp. announced on Friday that the stock exchange has approved the updated timetable for its follow-on offering, which could raise up to P6 billion to fund the company’s projects.
PSKXF PHSXY PSE DD
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...